All
CURExtra - Monitoring for Bladder Cancer Recurrence
October 23rd 2008Bladder cancer has one of the highest recurrence rates, but there are many tests and ways to monitor for early detection including, urine cytology, cystoscopy, BladderChek, UroVysion, FISH and ImmunoCyt Bladder Cancer Monitoring Test.
CURExtra - Evista Gives Women Another Choice for Preventing Breast Cancer
October 23rd 2008The STAR (Study of Tamoxifen and Raloxifene) trial, one of the largest breast cancer prevention trials ever conducted, showed that five years of Evista is as effective as tamoxifen in lowering risk of developing breast cancer, giving high-risk women a new option for prevention
CURExtra - Prostate Cancer Therapy: Men Guided by What They Fear, What They Hear
October 23rd 2008Choosing which cancer treatment is right for you is tough, but it is important to weigh the risks and benefits of each option and consider getting a second opinion, and studies show that most men diagnosed with prostate cancer base treatment decisions on preconceived ideas and fears or stories heard from other patients rather than logical evaluation of each treatment option—chemotherapy, radiation, surgery—and information from doctors.
CURExtra - Better Treatments/Better Healthcare
October 23rd 2008With research focused on targeted therapies that are less toxic, patients with advanced and rare cancers once considered incurable are being diagnosed earlier with better screening and diagnostic tests and living longer with new treatments like Xeloda for advanced or metastatic colorectal cancer.
Researchers Focus On Hormone-Negative Breast Cancer
October 23rd 2008Women with hormone-negative breast cancers may not be able to benefit from tamoxifen and aromatase inhibitors, but a subset of patients with HER2-positive breast cancer are able to take advantage of advances such as Herceptin and Tykerb. For women with hormone- and HER2-negative cancers, or triple negative, new research into what drives these cancers and prevent recurrence may increase treatment options and benefit this population.
CURExtra - The Future of Vaccine Therapies as Cancer Treatment
October 23rd 2008With the Food and Drug Administration requesting more information about the efficacy of Provenge, an investigational vaccine for hormone-refractory prostate cancer and what many expected to be the first vaccine approved to treat cancer, one may wonder when a therapeutic vaccine will finally reach patients outside clinical trials. But as researchers learn more about the immune system, develop better vaccines, and find how best to study their effects on cancer, vaccines are still expected to be an important player in the future of cancer therapy.
CURExtra - Making Progress: 2007 in Review
December 31st 2007The American Society of Clinical Oncology (ASCO) 2007 top Clinical Cancer Advances: Major Research Advances in Cancer Treatment, Prevention, and Screening saw advances in liver cancer, better screening methods for breast cancer, and the first vaccine to prevent cervical cancer—each advancement in prevention, screening, and treatment brings researchers one step closer to improving quality care for all people affected by cancer.